Dalba Got Back? Use of Dalbavancin for the Treatment of Vertebral Osteomyelitis

Abstract Data evaluating dalbavancin use for vertebral osteomyelitis remain limited. In our retrospective cohort, 29 of 34 (85.3%) patients completed their dalbavancin course. Adverse reactions occurred for 6 (17.6%) and infection recurrence in 3 (8.8%) within 90 days. Dalbavancin appears to be safe...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Open Forum Infectious Diseases 2024-03, Vol.11 (3), p.ofae070-ofae070
Hauptverfasser:	Streifel, Amber C, Strnad, Luke C, Sikka, Monica K, Varley, Cara D, Makadia, Jina, Sukerman, Ellie, Douglass, Alyse H, Mayer, Heather, Young, Kathleen, Lewis, James S
Format:	Artikel
Sprache:	eng
Schlagworte:	Clinical Trials and Therapeutics Complications and side effects Dalbavancin Dosage and administration Drug therapy Osteomyelitis Patient outcomes Spinal diseases
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Abstract Data evaluating dalbavancin use for vertebral osteomyelitis remain limited. In our retrospective cohort, 29 of 34 (85.3%) patients completed their dalbavancin course. Adverse reactions occurred for 6 (17.6%) and infection recurrence in 3 (8.8%) within 90 days. Dalbavancin appears to be safe and well-tolerated for vertebral osteomyelitis.
ISSN:	2328-8957 2328-8957
DOI:	10.1093/ofid/ofae070